Next Move Strategy Consulting
COVID-19 Diagnostics Market
Market 2023
Forecast 2030
CAGR 2024–2030
$42.09B
$74.17B
8.4%
www.nextmsc.com
Section 01 · Market Sizing
Market Landscape & Size The global COVID-19 Diagnostics Market sits at a strategic inflection point large installed base, recurring reagent revenue, and an 8.4% CAGR through 2030.
Market Size · 2023
Forecast · 2030
$42.09B
$74.17B
Coverage
28
8.4%
Countries profiled 10 companies · 5 segments
Growth Trajectory
Key Findings
USD Billion · 2023 → 2030
~$58B
Source · NMSC Diagnostics Market Report 2024
$74.17B
▸$32B incremental opportunity between 2023 and 2030.
$42.09B
▸Recurring reagent revenue. Reagents & kits drive 70%+ of repeat testing economics. ▸North America leads. Advanced healthcare infrastructure, regulatory approvals, anchor incumbents. ▸APAC accelerating. China & India case volumes and governmentfunded programs. ▸CRISPR & AI inflection. IP-rich adjacencies for early movers.
2023
2027E
2030
Base year
Mid-cycle
Forecast
Industry Ecosystem · Segmentation Three core axes that determine market capture and durable revenue streams
By Product & Service
Instruments · Reagents & Kits · Services
By Technology
By End Use
PCR · ELISA · LFIA · Others
Labs · Hospitals · Clinics · Others
PCR remains the gold standard; LFIA enables point-ofcare expansion in mass-market settings.
Hospitals & diagnostic centers anchor B2B distribution; point-of-care extends reach.
Regional Distribution of Demand North America
High
Dominant
Europe
Strong
$32B of new revenue over 6 years —
Surging
durable for reagent-led, recurring players.
Mature
Asia-Pacific Fastest
Source · Next Move Strategy Consulting · COVID -19 Diagnostics Market Report
02 / 06
Section 02 · Demand & Opportunity
Growth Drivers & Opportunities Four interlocking forces drive the 8.4% CAGR — variant-driven recurring demand, technology pivots, regional case surges, and government-funded scale-up.
Driver · 01
Driver · 02
Variant-Driven Recurring Demand
Government & Multilateral Funding Asian Development Bank approved a USD 1.5 billion loan to India in November 2021 to expand vaccine procurement — directly lifting adjacent diagnostic scale-up. Impact · High
Impact · High
Driver · 03
Driver · 04 · The Wildcard
At-Home & Point-of-Care Expansion
CRISPR, AI & Digital Diagnostics
Rapid antigen lateral-flow immunoassay (LFIA) kits democratize testing —
moving diagnostics out of central labs into clinics, workplaces, and consumer households.
Impact · Transformative
Impact · Sustained
Regional Opportunity Map Where incremental growth will concentrate through 2030
North America
Dominant
Rest of World
Pivot
Surging
Emerging LATAM, ME, Africa — long-tail scaling.
Source · Next Move Strategy Consulting · COVID -19 Diagnostics Market Report
03 / 06
Section 03 · Competitive Landscape
Competitive Scenario Ten global incumbents set the pace — pursuing variants at speed, multiplexing respiratory panels, and consolidating distribution into hospital channels.
Competitive Structure
Top 10 profiled companies · All pursuing scale through R&D, geographic expansion & partnerships Top 10 Players · Market Coverage Profiled in NMSC's 2024 report — ranked by global footprint & product breadth
01
02
03
F. HoffmannLa Roche
Abbott Laboratories
Danaher Corporation
Antigen leader
Cepheid platform
06
07
Quidel Corporation
bioMérieux SA
05
Quest Diagnostics
Immunoassays
Hologic Inc.
Siemens Healthineers Hospital channel
09
10
Thermo Fisher
PerkinElmer Inc.
Reagents scale
Diagnostics arm
Strategic Moves & Positioning Recent activity by category · Last 24 months Hologic · Nov 2022 · Product Launch
Roche · Sep 2022 · Variant Detection
Panther Fusion SARS-CoV-2 / Flu A/B / RSV assay rolled out in EU ahead of respiratory season.
Launched BA.2.75-differentiating COVID-19 test — speed-tomarket on emerging variants.
Strategy · Multiplex respiratory pivot to defend share post-pandemic.
Quest Diagnostics · Through Feb 2022 · Volume
72.2M+ COVID-19 molecular & serology tests performed since 2020.
Product launches, partnerships & geographic expansion dominate the playbook.
Strategy · Service scale — biggest North-American test throughput.
Investor Reading · Competitive Dynamics
Consolidated oligopoly · Innovation window still open Strength
Risk
Top 10 control reagent supply, hospital contracting &
Regulatory delays & commodity pressure on antigen
EU/CE-IVD approvals — high switching cost.
kits compress margins for late entrants.
Source · Next Move Strategy Consulting · COVID -19 Diagnostics Market Report
Opportunity
CRISPR & AI-native diagnostics → most likely M&A targets for incumbents through 2030.
04 / 06
Section 04 · Investor Takeaways
Strategic Outlook Five theses that translate the $42.09B → $74.17B trajectory into concrete investment & strategy moves for capital allocators and BD teams.
Five Investor & Strategy Theses Frameworks for capital allocation, BD targeting & partnership scouting
01
The market is large, growing and recurring — not a one-shot pandemic line item.
02
Asia-Pacific is the highest incremental growth pocket. China alone has reported 98.9M+ confirmed cases (Jan 2020 – Feb 2023); ADB funding is unlocking India scale-up. North America stays the largest single market.
03
Reagents, kits & point-of-care are the highest-margin plays.
04
Variant-driven R&D arms race favors speed-to-market challengers. Roche's BA.2.75 test (Sept 2022) and Hologic's multiplex respiratory assay (Nov 2022) prove cycle-time advantage is real competitive currency.
05
CRISPR & AI-native diagnostics are the next M&A wave.
Headline KPIs — At a Glance
$42.09B
$74.17B
8.4%
10 / 28
Market 2023
Forecast 2030
CAGR 2024–30
Players · Countries
Recommended Next Steps
› Diligence reagent/kit exposure via 5 LFI & PCR specialists | › Map M&a targets in CRISPR & AI diagnostics | › Build APAC distribution thesis around India
Source · Next Move Strategy Consulting · COVID -19 Diagnostics Market Report
05 / 06
Section 05 · Connect
End of Brief
Thank You. Reach the Research Team
Direct Contact Lines Official Website
W P
www.nextmsc.com
Read the Full Report
Contact Number
Click here for the complete report
+1 857 758 5017 Email
info@nextmsc.com
E
Request Access →
Request Access →
Follow Us
in
f
YouTube
𝕏
◉
Twitter / X
06 / 06